{"type":"trials","record":{"id":87200,"source_id":"isrctn","external_id":"ISRCTN74548520","title":"Diffuse laser treatment for prophylaxis of the fellow eye with age-related maculopathy in patients with exudative age-related macular degeneration (AMD)","brief_summary":"Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. The formation of abnormal blood vessels (Choroidal Neovascular Vessels = CNV) under the retina is the main cause of visual loss. It is often referred to as 'wet' AMD. Once the first eye is affected, the other eye has a high risk of developing the disease. This risk is increased (>70% in 5 years) if the fellow eye has signs of early disease in the form of yellow deposits known as drusen. Drusen disappear in over 60% of eyes treated with focal laser treatment. However, this type of laser can cause focal damage to the eye leading to a slight increase risk of developing CNV. Nonetheless, those who do not develop this complication, have better vision. We propose to use diffuse laser treatment to make drusen disappear, in which laser energy is transmitted to a larger area of the retina. As the laser energy is applied diffusely, it is unlikely to cause focal damage and hence it is possible that this can reduce the risk of developing CNV. Diffuse laser is has previously been used as a treatment for wet AMD, and it has been shown to be a safe procedure. The aim of this study is to evaluate whet…","overall_status":"Completed","phases":[],"study_type":"Interventional","sponsor":"Record Provided by the NHSTCT Register - 2006 Update - Department of Health","enrollment":0,"countries":["United Kingdom","England"],"start_date":"2005-07-01","completion_date":"2009-01-01","last_update_date":"2016-04-15","source_url":"https://www.isrctn.com/ISRCTN74548520","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"Not Specified","age_range":"Senior","comparator":null,"attribution":"Source: ISRCTN ISRCTN74548520; retrieved 2026-09-25","interventions":["Other"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Rate of development of CNV","Not provided at time of registration"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Eye Diseases: Age-related macular degeneration (AMD)","Age-related macular degeneration (AMD) is one of the leading causes of blindness in the western world. Currently there…","Other"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn74548520","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2005-07-01 to 2009-01-01","comparator":null,"confidence":"structured-source","population":"Not Specified · Senior","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.601Z","intervention":["Other"],"participants":0,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Rate of development of CNV","Not provided at time of registration"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87200","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}